Information Provided By:
Fly News Breaks for October 13, 2015
HTWR
Oct 13, 2015 | 08:36 EDT
Leerink analyst Danielle Antalffy lowered her price target for HeartWare after the company disclosed another delay in the MVAD trial beyond the current November expectation. Antalffy does not expect HeartWare will permanently halt the CE Mark trial. She expects the company to restart the trial within the next 12 months and reiterates an Outperform rating on the name.
News For HTWR From the Last 2 Days
There are no results for your query HTWR